usa finalist product of the year botanical 20230523-10

US product, Red Yeast Rice, is a finalist for the Nutraingredient USA Awards 2023!

  🌟 Exciting News! Our US product, Red Yeast Rice, is a finalist for the Nutraingredient USA Awards 2023! 🌟 Did you know that 80% of Americans have low or moderate cardiovascular health, often requiring multiple medications and devices to manage their cholesterol and blood sugar levels? The vicious cycle of cardiovascular health and diabetes is well-known, but dyslipidemia and AGE accumulation accelerate organ inflammation and lead to such deterioration. Moreover, the Western diet, which is full of AGEs, and COVID-19 have aggravated this already grim scenario. At SunWay, we’re both grateful and thrilled that the judges for the NutraIngredients USA Awards have selected our US ANKASCIN 568-R product as a Finalist in the 2023 Botanical category. Let’s root for Red Yeast Rice to win the championship together! Learn more about how #ANKASCIN568 can manage cardiovascular health and blood sugar: https://sunway.cc/tw/ankascin-568-r-when-science-meets-market-trend-meets-government-policy/ #NutraingredientUSA #Finalist #RedYeastRice #CardiovascularHealth #BloodSugarManagement #Innovation   Disclaimer: This communication is only intended for business-to-business. Nothing on this page is meant to be perceived as an approved claim by regulatory authorities.

Ankascin 568-R ingredient image1-20230331

ANKASCIN® 568-R – When science meets both market trend and government policies

  “The superior effects of MS and AK in ANKASCIN® 568-R show significant results, from managing glycation and inflammation to improving hyperglycemia, hyperlipidemia, hypertension, and cognitive health. This novel ingredient is clinically proven, safe, has multiple applications in dietary supplements and functional food, is compliant with EU and US regulations, and provides excellent support for healthy aging.”   According to the WHO, around one in ten people in Europe or US has diabetes, which means that if you go out with your relatives, there’s a good chance that the person you’re arm-in-arm with is someone who has diabetes. Chronic diabetic complications, including hyperlipidemia, hypertension, or Alzheimer’s disease, have been related to advanced glycation end product (AGE) accumulation. Glycation and AGEs lead to accelerated organ aging, thus causing the vicious cycle of tissue glycation and aging. However, the Western diet, which is full of AGEs, and COVID-19 have aggravated this already grim scenario. Reports show that patients with hyperglycemia and COVID-19 have a 2-to-4-fold risk of severe COVID-19 or death than those without diabetes. ANKASCIN® 568-R is a state-of-the-art ingredient containing high MS and AK levels. It addresses the root cause, mainly via PPARγ/Nrf2 pathways, to manage anti-glycation, antioxidant, and anti-inflammation and acts synergistically in improving the impairment of pancreatic β-cell function (blood glucose regulation), resolving lipid plaque accumulation in the blood […]

ANKASCIN 568-R has been recognized as a finalist for the Healthy Aging Ingredient of the Year at the Nutraingredients Awards 2023.

🎉We are thrilled to announce that ANKASCIN 568-R has been recognized as a finalist for the Healthy Aging Ingredient of the Year at the Nutraingredients Awards 2023. It is a cutting-edge ingredient that has been clinically proven to support blood glucose management, cardiovascular health, memory, cognitive health, and healthy aging. The uniqueness of ANKASCIN 568-R is that it contains high levels of Monascin and Ankaflavin, two active compounds that address the root cause of aging-related factors like advanced glycation end products, inflammatory cytokines, and reactive oxygen species via PPARγ/Nrf2 pathways. We are honored to be recognized for our commitment to innovation and excellence in the field of health and wellness. With growing public interest in anti-aging nutritional solutions, ANKASCIN 568-R fills a gap in the healthy aging supplement market.💪 Congratulations to all the finalists, and we look forward to continuing to drive innovation in the industry! Want to know more about ANKASCIN 568-R? contact us: globalservice@sunway.cc or call us at +886-2-2792-9568. #NutraingredientsAwards #HealthyAging #Innovation #ANKASCIN568R #Monascin #Ankaflavin #HealthAndWellness   Disclaimer: This communication is only intended for business-to-business. Nothing on this page is meant to be perceived as an approved claim by regulatory authorities.

2023延緩衰老健字號(英文)-20230320

ANKASCIN® 568 product has successfully received a health certificate for Anti-aging Support.

According to WHO, currently, more than 55 million people live with dementia worldwide, and there are nearly 10 million new cases every year. The most common type (60-70%) of dementia is Alzheimer’s disease (AD), a progressive disease characterized by memory loss, language breakdown, and eventually, death. The main pathological factor for AD is thought to be the progressive accumulation of amyloid beta (Aβ) peptides in the brain, generated by the cleavage of the amyloid precursor protein (APP) by a combination of β-secretases and γ-secretases. Hyperphosphorylation of tau, a microtubule-associated protein which aggregates to form tangles, also damages the brains of patients with AD. This year, we’re excited to announce that ANKASCIN® 568 product has successfully received a health certificate for “Anti-aging” Support. SunWay research demonstrates the protective effect of ANKASCIN® 568 in 4 aging models: Amyloid β-Infused Rats In this study, the effects of dietary administration of ANKASCIN® 568 on memory and learning abilities are confirmed in an animal model of AD rats infused with Aβ40 into the cerebral ventricle. During continuous Aβ40 infusion for 28 days, ANKASCIN® 568 administration potently reverses the memory deficit in the memory task. Aβ40 infusion increases acetylcholinesterase activity, reactive oxygen species, and lipid peroxidation and decreases total antioxidant status and superoxide dismutase activity in brain, but these damages were potently reversed by ANKASCIN® 568 administration. The protection provided […]

sunway president tsai

SunWay Biotech had earned recognition from President Tsai of Taiwan

President Tsai Ing-wen met the 2022 Outstanding Biotechnology Industry Award winners on 23rd February. She emphasized that the government will continue to invest resources and adjust and amend relevant laws and regulations to improve the competitiveness of the biotechnology and medical industry continuously. Thus, technology and medical enterprises will develop more vigorously and create more welfare for the public. SunWay Biotech is committed to applying diverse and effective microorganisms and developing efficient and unique fermentation processes to provide high-quality products that ensure carefree health across the globe. In addition to winning the Taiwan BIO Award-Advanced National Innovation Award” for two consecutive years in 2020 and 2021, SunWay was honored to be awarded the Gold Award of 2022 Taiwan BIO Award! SunWay was invited to meet with President Tsai and discuss with the President and other participants how to continuously improve the competitiveness of the biotechnology and medical industry and become Taiwan’s next trillion-dollar industry! President John Pan of SunWay Biotech also expressed his gratitude to every colleague, customer, shareholder, and the most important technological inventor, Professor Tzu-Ming Pan, for allowing SunWay to create another sacred mountain for Taiwan! Source: Office of the President

2022精進獎3-600x376

Professor Tzu-Ming Pan and SunWay Biotech were triple awarded National Innovation Award Excelsior Award!

With the continuous innovation and advancements in R&D, the project “Study on Application of Red Mold Rice- Improvement of Memory and Learning Abilities of Alzheimer’s Patient and Metabolic Symptom”, researched by Professor Tzu-Ming Pan and SunWay Biotech research team, was triple awarded National Innovation Award Excelsior Award on 23 Dec 2022! For more information: https://reurl.cc/ROAejr

probiotic, microbiome

Vigiis® 101-LAB probiotic shows benefits to improve gut microflora.

The first clinical study, which has been published in Heliyon, documents that Vigiis® 101-LAB significantly increases the bacterial counts of Bifidobacterium spp. and Lactobacillus spp. in feces in just one week, and maintains those elevated counts for four weeks. Thirty-six healthy subjects completed a randomized, double-blind, placebo-controlled 4-week study. The administration group took 50 mg Vigiis® 101-LAB /one capsule/day (= 5 billion NTU 101 CFU/day) for four weeks. After just one week of administration, the bacterial counts of Bifidobacterium spp. and Lactobacillus spp. in the feces of the treatment group were significantly higher than the placebo group. After four weeks, the treatment group’s bacterial counts of Bifidobacterium spp. and Lactobacillus spp. were 4.01-fold and 4.25-fold higher than the placebo group. These results indicate that supplementation of Vigiis® 101-LAB significantly increases good bacteria in the gut in just one week and maintains those elevated counts for four weeks. People can benefit from compelling effects of Vigiis® 101-LAB, efficacious and science-supported probiotic. John Pan, President of SunWay Biotech, commented that “It is important to maintain a healthy microbial balance in the gut microbiome with quality and clinically proven ingredients.” For more information, please get in touch with us: globalservice@sunway.cc   Reference: Effects of Vigiis 101-LAB on a healthy population’s gut microflora, peristalsis, immunity, and anti-oxidative capacity: A randomized, double-blind, placebo-controlled clinical study. (link) […]

1-英文

Recommendations regarding red yeast rice supplementation

An international panel of lipid experts issued recommendations regarding red yeast rice supplementation that   People who are ❗️ unwilling to take a statin or other lipid-lowering drug or ❗️ with confirmed statin intolerance  may consider red yeast rice supplementation   People who are ❗️ hypersensitivity to monacolin K/lovastatin or any of the excipients ❗️ acute liver disease or severe renal impairment (eGFR <30 mL/min), or ❗️ with a muscle disease 👉should not consider taking traditional red yeast rice supplement. (which means red yeast rice supplement containing monacolin K)   Using only red yeast rice manufactured according to ✅ good manufacturing practices and ✅ containing no more than about 2 ppm of citrinin. (EU’s maximum levels of citrinin: 100 ppb)    SunWay Biotech applies the strictest limit, ANKASCIN 568-R, the only red yeast rice that doesn’t contain any Monacolin K/lovastain in the world. All of its benefits and safety are verified by clinical studies and liver/kidney safety assessments. Thus, consumers do not need to be concerned about drug interactions or overdose. Furthermore, ANKASCIN 568-R goes through a patented extraction process that can comply with the regulations of citrinin for each country. We are guaranteed that this ingredient will start a new page for your consumers.💪💪   Source: https://lnkd.in/gBDE-q-c https://lnkd.in/g8yTnSTc

總經理被頒獎

We are honored to be awarded the Gold Award of 2022 Taiwan BIO Award!

  We are honored to be awarded the Gold Award of 2022 Taiwan BIO Award! After three months of evaluation, the Taiwan Bio Industry Organization (TBIO) has selected 14 companies as the 2022 winners of the Taiwan BIO Awards by evaluating their operational performance, development potential, research and development capabilities, and social contribution. SunWay Biotech is honored to be listed as one of the winners awarded the Gold Award of 2022 Taiwan BIO Award! “SunWay Biotech Co., LTD.” was founded in 2007. As a leading world-class dietary supplement expert, SunWay Biotech aims to apply diverse and effective microorganisms, and develop efficient and unique fermentation processes, to provide high-quality products that ensure carefree health across the globe. “We hope to become the Intel in the dietary supplement industry, as the CPU of Intel which can be the core of the different computer brands. Our original, functional branded ingredients will play a vital role like the heart in the global dietary supplement company,” said John Pan, President of SunWay Biotech. Meanwhile, SunWay has performed many clinical trials, including regulating blood lipids, blood sugar, blood pressure, and Alzheimer’s disease, to demonstrate the benefits of our patented ingredients- ANKASCIN 568-R in Taiwan, Tientsin, and Los Angeles. Moreover, we also have two clinical trials in progress related to blood lipids regulation (HDL-C) and blood sugar modulation […]

cardiovascualr health ankascin

ANKASCIN® 568-R red yeast rice extract shows benefits to manage total cholesterol and LDL-C

The first clinical study, which has been published in the Journal of Food and Drug Analysis, documents that ANKASCIN® 568-R is effective in reducing subjects’ serum cholesterol and low-density lipoprotein cholesterol (LDL-C) to nearly desirable levels in as little as 4 weeks and were maintained in 8 weeks. Forty subjects (Inclusion criteria: LDL-C in the range of 130-190 mg/dL and serum cholesterol greater than 180 mg/dL) completed the double-blind, placebo-controlled randomized 12-week study. The administration group took 110 mg ANKASCIN® 568-R/one capsule/day for eight weeks. After four weeks of treatment (110 mg ANKASCIN® 568-R/day), the changes in the lipid levels showed that the active products had a more favorable effect than the placebo. Compared to the baseline, statistically significant decreases of 11.9% and 19.0% were observed in TC and LDL-C levels, respectively (p < 0.05 for all pairs). This study demonstrated that subjects administered 110 mg of ANKASCIN® 568-R for more than four weeks exhibited a significant reduction in serum TC and LDL-C levels. To assess the safety of this ingredient, scientists assayed aspartate transaminase (AST) and alanine aminotransferase (ALT) levels in the liver, and blood urea nitrogen (BUN), creatinine, and uric acid levels in the kidney. The results imply no significant effect on renal metabolism and physiological function. These results indicate that supplementation of ANKASCIN® 568-R reduces the risks of serum TC and […]